Hyperimmune Globulins Market Forecasts to 2030 – Global Analysis By Type (Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Rho(D) Immunoglobulins, Tetanus Immunoglobulins and Other Types), By End User (Hospitals & Clinics, Blood Banks and Donation Cen

Hyperimmune Globulins Market Forecasts to 2030 – Global Analysis By Type (Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Rho(D) Immunoglobulins, Tetanus Immunoglobulins and Other Types), By End User (Hospitals & Clinics, Blood Banks and Donation Centers, Government Institutions and Other End Users) and By Geography

According to Stratistics MRC, the Global Hyperimmune Globulins Market is accounted for $2.01 billion in 2023 and is expected to reach $3.69 billion by 2030 growing at a CAGR of 9% during the forecast period. Hyperimmune globulins are specialized preparations of antibodies that are derived from the blood plasma of individuals who have a high concentration of antibodies against a specific pathogen or antigen. These antibodies are collected from donors who have been exposed to or vaccinated against a particular disease, resulting in their immune system producing a robust antibody response. Hyperimmune globulins are then processed, purified, and concentrated to contain high levels of specific antibodies. These preparations are used for passive immunization, providing immediate and targeted immunity against particular infections.

Market Dynamics

Driver

The prevalence of various infectious diseases

The infectious diseases continuing to pose significant global health challenges, there is an ever-growing demand for targeted and effective therapies. Hyperimmune globulins, containing high concentrations of specific pathogen-fighting antibodies, are instrumental in preventing and treating such diseases. The increasing incidence of infectious diseases, ranging from hepatitis to rabies, prompts healthcare systems to invest in hyperimmune globulin products, as they offer critical support for patients, especially in cases where conventional treatments may be limited. As the world faces both known and emerging infectious threats, the demand for hyperimmune globulins is expected to remain robust, further bolstering their market presence and the development of new therapies to combat these diseases.

Restraint

Limited availability of donors

Hyperimmune globulins are derived from individuals who possess specific antibodies against a particular pathogen. Finding an adequate number of donors with the necessary antibodies can be a challenging and resource-intensive process. This limitation can result in difficulties in scaling up production to meet the demand for hyperimmune globulins, particularly for diseases with a low prevalence or for emerging infectious threats. Moreover, ensuring a consistent and sustainable supply of qualified donors is essential for maintaining product quality and efficacy. This constraint necessitates innovative approaches, such as the development of artificial antibodies or more efficient donor recruitment and collection strategies, to overcome the limited availability of donors in the hyperimmune globulins market.

Opportunity

Growing awareness among healthcare professionals

As healthcare providers become more informed about the therapeutic benefits of hyperimmune globulins in addressing specific infectious diseases and conditions, they are more likely to recommend and administer these specialized immunoglobulin products to their patients. Enhanced awareness can lead to earlier diagnosis and treatment, resulting in better patient outcomes. Additionally, informed healthcare professionals can contribute to increased research, development, and clinical utilization of hyperimmune globulins for both existing and emerging infectious diseases. This can foster collaboration between pharmaceutical companies and healthcare practitioners, ultimately driving the growth and accessibility of hyperimmune globulin therapies, while improving patient care and public health outcomes.

Threat

Limited shelf life

Hyperimmune globulin products typically have a relatively short shelf life, which can lead to logistical challenges in terms of storage, transportation, and distribution. Maintaining the required temperature and storage conditions throughout the supply chain can be complex and costly. This constraint can result in product wastage, especially if the demand is not met within the specified timeframe, leading to financial losses. It also necessitates efficient inventory management to prevent expiration and product shortages. To mitigate this threat, there is a need for innovations in storage and preservation techniques, extended shelf life products, and improved distribution systems to ensure that hyperimmune globulins reach patients in a timely and effective manner.

Covid-19 Impact

The COVID-19 pandemic has accelerated the adoption of remote healthcare, increasing the demand for home Hyperimmune Globulins. With more people avoiding healthcare facilities, these devices allow individuals to monitor their blood pressure from home, aiding in the management of chronic conditions. Telehealth consultations and remote monitoring have become essential, making digital and smartphone-integrated monitors more popular. The pandemic has underscored the importance of self-care and early detection, driving innovation and convenience in blood pressure monitoring technology during this period.

The hospitals & clinics segment is expected to be the largest during the forecast period

Hospitals and clinics are significant in the hyperimmune globulins market as primary points of care and administration for patients in need of these specialized immunoglobulin therapies. These healthcare facilities are central in the distribution and utilization of hyperimmune globulin products, serving as hubs for diagnosis, treatment, and preventive measures against specific infectious diseases. Hospitals and clinics are responsible for diagnosing conditions that require hyperimmune globulins, administering treatments, and managing patient care. They also serve as key advocates in raising awareness about the benefits of hyperimmune globulins and, in many cases, are responsible for procuring and stocking these products. The success and growth of the hyperimmune globulins market are closely tied to the engagement and proactive role of hospitals and clinics in patient care and public health.

The rabies immunoglobulins segment is expected to have the highest CAGR during the forecast period

The rabies immunoglobulins segment is expected to witness significant growth over the forecast period driven by increasing awareness of rabies prevention, a rising incidence of rabies in certain regions, and improved production techniques. Governments and healthcare organizations have initiated rabies control programs to address this public health concern. Moreover, ongoing research and development efforts aim to enhance the efficiency and affordability of rabies immunoglobulins. The critical role that rabies immunoglobulins play in preventing and treating rabies ensures their continued growth within the broader hyperimmune globulins market.

Region with largest share

The market for Hyperimmune Globulins in North America is expected to witness robust growth in recent years. This surge can be attributed to rising awareness about passive immunization, especially in high-risk populations. Increasing incidence of infectious diseases and the need for immediate, targeted immunity have driven demand. Additionally, strategic collaborations between healthcare institutions, research organizations, and pharmaceutical companies have accelerated research and development efforts. With a well-established healthcare infrastructure, stringent regulatory framework, and growing healthcare expenditure, North America is poised to continue leading in hyperimmune globulins market growth.

Region with highest CAGR

During the forecast period, North America is anticipated to witness lucrative growth. Hyperimmune globulins play a critical role in healthcare throughout the Asia-Pacific region. These specialized antibody preparations are vital for addressing and preventing a range of infectious diseases prevalent in this diverse and populous area. Diseases like hepatitis B, rabies, and tetanus are significant public health concerns. Moreover, Asia-Pacific's vast geographic and demographic diversity underscores the importance of these preparations in safeguarding public health and mitigating the impact of infectious diseases, making them an essential component of the healthcare landscape in the region.

Key players in the market

Some of the key players in Hyperimmune Globulins market include ADMA Biologics, Biotest, China National Biotec Group Company Limited (CNBG), CSL Behring, Emergent (Cangene), Grifols, Hualan Bio, Kamada, Kedrion, Shanghai Raas Blood Products Co. Ltd and Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.

Key Developments

In July 2023, Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, has announced that China's National Institutes for Food and Drug Control (NIFDC) has approved BPL's human Albumin product for release to the Chinese market. In 2022, Kedrion joined forces with BPL, a UK-based company with over 60 years of experience in the supply of high-quality plasma-derived medicines for the treatment of rare diseases.

In March 2023, Grifols entered into a collaboration and licensing agreement with Selagine to develop immunoglobulin (Ig) eye drops to treat dry eye disease. Under the terms of the agreement, Grifols will have worldwide exclusive commercial rights to Selagine’s treatment once it receives the regulatory authorization, expected in early 2029.

In January 2022, LFB and Kedrion signed an industrial cooperation agreement to supply immunoglobulins to meet patient demand in France. Two leading European pharmaceutical companies, LFB and Kedrion, are joining forces in an industrial cooperation agreement to increase the availability of immunoglobulin, a plasma-derived medicine, for patients in France.

Types Covered
• Hepatitis B Immunoglobulins
• Rabies Immunoglobulins
• Rho(D) Immunoglobulins
• Tetanus Immunoglobulins
• Other Types

End Users Covered
• Hospitals & Clinics
• Blood Banks and Donation Centers
• Government Institutions
• Home Healthcare
• Pharmaceutical Companies
• Other End Users

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements